A szerzők egy 59 éves férfi esetét mutatják be, akinél először 1983-ban, majd 2000-ben végeztek vesetranszplantációt. Az első veseátültetést követően két évvel jelent meg az első laphámsejtes carcinoma a bőrön, majd 2003-tól évente legalább kettő praecancerosus laesio vagy nonmelanoma bőrdaganat sebészeti eltávolítása történt. Ezek a tumorok elsősorban a napfénynek kitett bőrterületeken jelentek meg, multiplexen. Tekintettel arra, hogy agresszív viselkedésűek lehetnek és recidívára hajlamosak, komplex kezelést alkalmaztak a betegnél, amely magába foglalta az immunszuppresszió során alkalmazott gyógyszerek megváltoztatását, illetve mezőterápiák alkalmazását. Az eset bemutatása kapcsán a szerzők áttekintik ezeket a kezelési lehetőségeket, hangsúlyozva, hogy nemcsak a bőrdaganatok minél korábbi felismerése és aktív kezelése szükséges, hanem a betegek megfelelő fényvédelemre való oktatása és bőrgyógyászati gondozása is a bőrtumorok kialakulásának megelőzése érdekében. Orv. Hetil., 2016, 157(24), 971–976.
Végső, G., Tóth, A., Toronyi, É., et al.: Changes in tumor characteristics in kidney transplanted patients over the last 40 years. Transplant. Proc., 2015, 47(7), 2198–2200.
Végső, Gy., Járay, J.: Malignant tumors following renal transplantation. [A veseátültetést követően kialakuló rosszindulatú daganatok.] Orv. Hetil., 2007, 148(45), 2115–2223. [Hungarian]
Végső, G., Toronyi, É., Hajdu, M., et al.: Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transplant. Proc., 2011, 43(4), 1261–1263.
Végső, Gy.: Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility. [A szervátültetést követő rosszindulatú daganatok problémája, különös tekintettel a lymphomában szenvedő, transzplantált betegeknél választandó immunszuppresszív kezelésre. A mycophenolsav, mint lehetőség.] Magy. Onkol., 2009, 53(2), 149–156. [Hungarian]
Tufaro, A. P., Azoury, S. C., Crompton, J. G., et al.: Rising incidence and aggressive nature of cutaneous malignancies after transplantation: An update on epidemiology, risk factors, management and surveillance. Surg. Oncol., 2015, 24(4), 345–352.
Tessari, G., Girolomoni, G.: Nonmelanoma skin cancer in solid organ transplant recipients: Update on epidemiology, risk factors, and management. Dermatol. Surg., 2012, 38(10), 1622–1630.
Brin, L., Zubair, A. S., Brewer, J. D.: Optimal management of skin cancer in immunosuppressed patients. Am. J. Clin. Dermatol., 2014, 15(4), 339–356.
Nemes, B., Toronyi, É., Rajczy, K., et al.: De novo malignant melanoma occurred in renal allograft: DNA typing to determine the origin of the tumour. Intervent. Med. Appl. Sci., 2010, 2(1), 31–36.
Mougel, F., Kanitakis, J., Faure, M., et al.: Basosquamous cell carcinoma in organ transplant patients: A clinicopathologic study. J. Am. Acad. Dermatol., 2012, 66(5), e151–e157.
Zwald, F. O., Brown, M.: Skin cancer in solid organ transplant recipients: Advances in therapy and management. Part I. Epidemiology of skin cancer in solid organ transplant recipients. J. Am. Acad. Dermatol., 2011, 65(2), 253–261.
Rodríguez-Acosta, E. D., Calva-Mercado, J. J., Alberú-Gómez, J., et al.: Patients with solid organ transplantation and skin cancer: determination of risk factors with emphasis in photoexposure and immunosuppressive regimen. Experience in a third level hospital. Gac. Med. Mex., 2015, 151(1), 19–24.
Mudigonda, T., Levender, M. M., O’Neill, J. L., et al.: Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: A review of single- and multicenter retrospective studies from 2006 to 2010. Dermatol. Surg., 2013, 39(3 Pt 1), 345–364.
Wheless, L., Jacks, S., Potter, K. A., et al.: Skin cancer in organ transplant recipients: more than the immune system. J. Am. Acad. Dermatol., 2014, 71(2), 359–365.
Jung, J. W., Overgaard, N. H., Burke, M. T., et al.: Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients? Int. J. Cancer, 2015, 138(2), 281–292.
Kuschal, C., Thoms, K. M., Schubert, S., et al.: Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp. Dermatol., 2012, 21(1), 2–6.
Chockalingam, R., Downing, C., Tyring, S. K.: Cutaneous squamous cell carcinomas in organ transplant recipients. J. Clin. Med., 2015, 4(6), 1229–1239.
Feuerstein, I., Geller, A. C.: Skin cancer education in transplant recipients. Prog. Transplant., 2008, 18(4), 232–242.
Francis, S., Berg, D.: Reducing skin malignancy risk in organ transplant recipients. Skin Ther. Lett., 2013, 18(1), 1–3.
Terhorst, D., Drecoll, U., Stockfleth, E., et al.: Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br. J. Dermatol., 2009, 161(Suppl. 3), 85–89.
Moloney, F. J., Almarzouqi, E., O’Kelly, P., et al.: Sunscreen use before and after transplantation and assessment of risk factors associated with skin cancer development in renal transplant recipients. Arch. Dermatol., 2005, 141(8), 978–982.
Bangash, H. K., Colegio, O. R.: Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr. Treat. Options Oncol., 2012, 13(3), 354–376.
Ritchie, S. A., Patel, M. J., Miller, S. J.: Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol. Surg., 2012, 38(10), 1604–1621.
Singh, M. K., Brewer, J. D.: Current approaches to skin cancer management in organ transplant recipients. Semin. Cutan. Med. Surg., 2011, 30(1), 35–47.
Ulrich, C., Arnold, R., Frei, U., et al.: Skin changes following organ transplantation. Dtsch. Arztebl. Int., 2014, 111(11), 188–194.
Zwald, F. O., Brown, M.: Skin cancer in solid organ transplant recipients: Advances in therapy and management. Part II. Management of skin cancer in solid organ transplant recipients. J. Am. Acad. Dermatol., 2011, 65(2), 263–279.
Penn, I.: Occurrence of cancers in immunosuppressed organ transplant recipients. Clin. Transpl., 1998, 147–158.
Penn, I.: Cancers in renal transplant recipients. Adv. Ren. Replace. Ther., 2000, 7(2), 147–156.
Lloyd, A., Klintmalm, G., Qin, H., et al.: Skin cancer evaluation in transplant recipients: A physician opinion survey with recommendations. Clin. Transplant., 2015, 29(2), 110–117.
Hofbauer, G. F., Anliker, M., Arnold, A., et al.: Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med. Wkly, 2009, 139(29–30), 407–415.
Imko-Walczuk, B., Kielbowick, M., Dębska-Ślizień, A., et al.: Skin cancers as contraindication to organ transplantation. Transplant. Proc., 2015, 47(6), 1547–1552.
Basset-Seguin, N., Baumann Conzett, K., Gerritsen, M. J., et al.: Photodynamic therapy for actinic keratosis in organ transplant patients. J. Eur. Acad. Dermatol. Venereol., 2013, 27(1), 57–66.
Mann, M., Berk, D. R., Petersen, J.: Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J. Drugs Dermatol., 2008, 7(7), 685–688.
Willey, A., Mehta, S., Lee, P. K.: Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol. Surg., 2010, 36(5), 652–658.
Hasson, A., Navarrete-Dechent, C., Nicklas, C., et al.: Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: a case-series of 16 patients. Indian J. Dermatol. Venereol. Leprol., 2012, 78(4), 448–453.
Togsverd-Bo, K., Omland, S. H., Wulf, H. C., et al.: Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: a randomized controlled trial. Am. J. Transplant., 2015, 15(11), 2986–2990.
Kovach, B. T., Murphy, G., Otley, C. C., et al.: Oral retinoids for chemoprevention of skin cancers in organ transplant recipients: results of a survey. Transplant. Proc., 2006, 38(5), 1366–1368.
Geissler, E. K.: Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant. Res., 2015, 4, 1–6.
Feldmeyer, L., Hofbauer, G. F., Böni, T., et al.: Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing. Br. J. Dermatol., 2012, 166(2), 422–424.
Chen, K., Craig, J. C., Shumack, S.: Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br. J. Dermatol., 2005, 152(3), 518–523.